Can acenocoumarol (Acitrom) cause skin necrosis?

Yes, Acitrom (acenocoumarol) can cause skin necrosis.

Acenocoumarol, like all coumarin anticoagulants, can cause skin necrosis—a rare but serious thrombotic complication that typically occurs between the third and eighth day of therapy. 1, 2

Mechanism and Timing

Skin necrosis from acenocoumarol results from extensive thrombosis of venules and capillaries within subcutaneous fat, not from direct drug toxicity 1, 2. This paradoxical thrombotic complication occurs because:

• Protein C (a natural anticoagulant) has a shorter half-life than the vitamin K-dependent clotting factors
• When acenocoumarol is started, protein C levels drop rapidly before factors II, IX, and X decline
• This creates a transient hypercoagulable state in the first week of therapy 3, 4

Peak incidence: Days 3-6 of treatment, though it can occur anytime in the first 10 days 5, 2

Risk Factors

While protein C deficiency (and less commonly protein S deficiency) is associated with this complication, skin necrosis also occurs in patients without these deficiencies 1, 2. The case reports confirm acenocoumarol-induced necrosis in patients with:

• Heterozygous protein C deficiency 3
• Normal protein C and S levels 4
• Acquired transient deficiency states (e.g., renal insufficiency) 4

Additional risk factors include obesity and local tissue factors 3.

Clinical Presentation

Patients develop:

• Painful ecchymotic lesions that progress to necrosis
• Most commonly affects areas with high subcutaneous fat (breasts, buttocks, thighs)
• Can occur on face, arms, and lower extremities 5
• Histology shows vessel thrombi and red blood cell extravasation 3

Critical Management Algorithm

If skin necrosis occurs:

1. Immediately discontinue acenocoumarol - it is considered contraindicated after this complication 2

2. Start therapeutic-dose parenteral anticoagulation (heparin or LMWH) immediately

3. If lifelong anticoagulation is required, you can cautiously restart acenocoumarol using this specific protocol 1, 2:

   • Begin with low-dose acenocoumarol (2 mg daily)
   • Maintain therapeutic parenteral anticoagulation coverage
   • Gradually increase acenocoumarol dose over 1 or more weeks
   • This prevents abrupt protein C depletion before clotting factor reduction
   • Case reports show this approach avoids recurrence 1, 2

4. Alternative: Switch to a non-coumarin anticoagulant (LMWH long-term, or direct oral anticoagulants if appropriate for the indication)

Important Caveats

• Do not confuse with "purple toe syndrome", which is a separate non-hemorrhagic complication from cholesterol emboli that occurs 3-8 weeks after starting therapy and presents with bilateral purple lesions on toes that blanch with pressure 2

• The term "coumarin-induced skin necrosis" is technically inaccurate since coumarin itself has no anticoagulant properties—it's the anticoagulant derivatives (acenocoumarol, warfarin) that cause this 5

• Acenocoumarol can also cause calciphylaxis (arteriolar calcification with thrombosis), particularly with prolonged use, which presents differently and resolves only after drug withdrawal 6

• Starting with lower initial doses and overlapping with parenteral anticoagulation from day 1 may reduce risk, though this is not definitively proven

The evidence consistently demonstrates that acenocoumarol carries the same skin necrosis risk as warfarin, with multiple case reports confirming this complication 5, 3, 4, 7.